tradingkey.logo

PAVmed Inc

PAVM
0.363USD
-0.013-3.48%
Horário de mercado ETCotações atrasadas em 15 min
7.31MValor de mercado
0.10P/L TTM

Mais detalhes de PAVmed Inc Empresa

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.

Informações de PAVmed Inc

Código da empresaPAVM
Nome da EmpresaPAVmed Inc
Data de listagemJul 27, 2016
CEODr. Lishan Aklog, M.D.
Número de funcionários39
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 27
Endereço360 Madison Avenue
CidadeNEW YORK
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal10017
Telefone12129494319
Sitehttps://pavmed.com/
Código da empresaPAVM
Data de listagemJul 27, 2016
CEODr. Lishan Aklog, M.D.

Executivos da empresa PAVmed Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
228.72K
--
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
226.67K
-2.16%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
215.00K
--
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
200.83K
--
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
162.19K
--
Mr. Michael A. Gordon
Mr. Michael A. Gordon
General Counsel, Secretary
General Counsel, Secretary
--
--
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--
Mr. Timothy (Tim) Baxter
Mr. Timothy (Tim) Baxter
Independent Director
Independent Director
--
--
Mr. Matt Riley
Mr. Matt Riley
Director of Investor Relations
Director of Investor Relations
--
--
Mr. Shaun M. O'Neil
Mr. Shaun M. O'Neil
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
228.72K
--
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
226.67K
-2.16%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
215.00K
--
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
200.83K
--
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
162.19K
--
Mr. Michael A. Gordon
Mr. Michael A. Gordon
General Counsel, Secretary
General Counsel, Secretary
--
--

Detalhamento da receita

Sem dados
Sem dados
Por Empresa
Por Região
Sem dados

Distribuição de ações

Atualizado em: ter, 7 de out
Atualizado em: ter, 7 de out
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Tasso Partners, LLC
9.17%
Sargent Investment Group, LLC
3.58%
First Manhattan Co. LLC
2.54%
Dubreville (Anthony Michael)
2.16%
Pavilion Venture Partners, L.L.C.
1.06%
Outro
81.49%
Investidores
Investidores
Proporção
Tasso Partners, LLC
9.17%
Sargent Investment Group, LLC
3.58%
First Manhattan Co. LLC
2.54%
Dubreville (Anthony Michael)
2.16%
Pavilion Venture Partners, L.L.C.
1.06%
Outro
81.49%
Tipos de investidores
Investidores
Proporção
Corporation
13.52%
Individual Investor
11.24%
Investment Advisor
9.64%
Investment Advisor/Hedge Fund
0.57%
Research Firm
0.27%
Hedge Fund
0.16%
Outro
64.60%

Participação acionária institucional

Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
89
2.26M
8.05%
+439.12K
2025Q2
101
5.16M
29.26%
+2.76M
2025Q1
106
5.16M
31.74%
+3.03M
2024Q4
110
2.41M
17.67%
+156.53K
2024Q3
120
2.58M
24.42%
+197.13K
2024Q2
133
1.94M
20.61%
-301.78K
2024Q1
169
2.19M
26.52%
+433.78K
2023Q4
185
1.60M
20.86%
-48.73K
2023Q3
208
1.30M
18.00%
-268.87K
2023Q2
221
1.26M
18.65%
-731.24K
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Tasso Partners, LLC
2.57M
12.12%
+2.57M
--
Feb 21, 2025
Sargent Investment Group, LLC
1.01M
4.74%
+1.01M
--
Jul 01, 2025
First Manhattan Co. LLC
714.10K
3.36%
--
--
Jun 30, 2025
Dubreville (Anthony Michael)
606.26K
2.85%
+606.26K
--
Aug 30, 2024
Pavilion Venture Partners, L.L.C.
297.11K
1.4%
--
--
Apr 22, 2025
Aklog (Lishan)
228.72K
1.08%
+150.00K
+190.54%
Sep 30, 2025
Glennon (Michael J)
231.67K
1.09%
+150.00K
+183.67%
Sep 30, 2025
White (Debra Jayne)
215.00K
1.01%
+150.00K
+230.77%
Sep 30, 2025
Sparks (Ronald M)
215.00K
1.01%
+150.00K
+230.77%
Sep 30, 2025
Baxter (Timothy E)
215.00K
1.01%
+150.00K
+230.77%
Sep 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Tipo
Proporção
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Data
Tipo
Proporção
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
KeyAI